ACTUALIZACIÓN:

The respiratory tract management is one of the most important topics in anesthesia. Between 50 and 70 % of the heart arrests occurring during general anesthesia are due to intubation difficulties. Obese patients are 30 % more likely of presenting difficult intubation with respect to normal weight patients. They also develop oxygen desaturation faster, increasing the complication risk. Taking into consideration the above reasons, the authors decided to write this article, with the aim of updating on the methods to approach the respiratory tract in those patients. The authors’ criteria and research outcomes on the theme are showed. It was concluded that even though the most used method to approach the airway in obese patients is the orotracheal intubation with direct vision, the use of a laryngeal intubation mask, flexible fiberscope and video laryngoscopes should be considered, especially in superobese patients.

[1]  N. Papadopoulos,et al.  Face masks, respiratory patients and COVID-19 , 2020, European Respiratory Journal.

[2]  M. Miravitlles,et al.  GesEPOC 2021: One More Step Towards Personalized Treatment of COPD. , 2020, Archivos de bronconeumologia.

[3]  F. Martín-Sánchez,et al.  Management and follow up of respiratory patients in the post-Covid-19 era: Are we ready yet? , 2020, Archivos de Bronconeumología (English Edition).

[4]  M. Miravitlles,et al.  A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future , 2020, International journal of chronic obstructive pulmonary disease.

[5]  M. Miravitlles,et al.  The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency , 2020, COPD.

[6]  D. Price,et al.  Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study. , 2020, Archivos de bronconeumologia.

[7]  P. Dorinsky,et al.  Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.

[8]  M. Martínez-García,et al.  Consensus Document on the Diagnosis and Treatment of Chronic Bronchial Infection in Chronic Obstructive Pulmonary Disease. , 2020, Archivos de bronconeumologia.

[9]  M. Miravitlles,et al.  Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease , 2020, Journal of clinical medicine.

[10]  M. Miravitlles,et al.  The right treatment for the right patient with COPD: lessons from the IMPACT trial , 2020, European Respiratory Journal.

[11]  J. Wedzicha,et al.  Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline , 2020, American journal of respiratory and critical care medicine.

[12]  D. Price,et al.  Predictive value of control of COPD for risk of exacerbations: An international, prospective study , 2020, Respirology.

[13]  A. Aldhahir,et al.  Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis , 2020, medRxiv.

[14]  G. Lippi,et al.  Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) , 2020, Respiratory Medicine.

[15]  J. Curtis,et al.  Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease , 2020, American journal of respiratory and critical care medicine.

[16]  M. Miravitlles,et al.  Spanish Implementation of the New International Alpha-1 Anitrypsin Deficiency International Registry: The European Alpha-1 Research Collaboration (EARCO). , 2020, Archivos de bronconeumologia.

[17]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[18]  M. Miravitlles,et al.  Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study. , 2020, Archivos de bronconeumologia.

[19]  M. Miravitlles,et al.  Clinical Control in COPD: A New Therapeutic Objective? , 2020, Archivos de Bronconeumologia.

[20]  J. López-Campos,et al.  The Clinical Implications of Triple Therapy in Fixed-Dose Combination in COPD: From the Trial to the Patient. , 2020, Archivos de bronconeumologia.

[21]  M. Miravitlles,et al.  Clinical Characteristics and Risk of Exacerbations Associated With Different Diagnostic Criteria of Asthma-COPD Overlap. , 2019 .

[22]  J. Soriano,et al.  Adjusting the Level of Intervention in Patients with Chronic Obstructive Pulmonary Disease According to the Risk Stratification Proposed by the Spanish COPD Guidelines (GesEPOC) Version 2017. , 2019 .

[23]  R. Golpe,et al.  Plasma Eosinophil Count and Patient-Centered Events in Chronic Obstructive Pulmonary Disease in Real-Life Clinical Practice. , 2019 .

[24]  E. Kerwin,et al.  Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial , 2019, Respiratory Research.

[25]  Meilan K. Han,et al.  Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. , 2019, The Lancet. Respiratory medicine.

[26]  B. Celli,et al.  Prognostic Validation Using GesEPOC 2017 Severity Criteria. , 2019, Archivos de bronconeumologia.

[27]  N. Zhong,et al.  Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study , 2019, ERJ Open Research.

[28]  J. Soriano,et al.  ACO: Time to move from the description of different phenotypes to the treatable traits , 2019, PloS one.

[29]  R. Golpe,et al.  Should Lung Function Be Included in the Risk Stratification of Chronic Obstructive Pulmonary Disease Proposed by GesEPOC? , 2019, Archivos de bronconeumologia.

[30]  F. Martinez,et al.  Pulmonary hypertension in chronic lung disease and hypoxia , 2019, European Respiratory Journal.

[31]  M. Miravitlles,et al.  Recommendations on non-Pharmacological Treatment in Chronic Obstructive Pulmonary Disease From the Spanish COPD Guidelines (GesEPOC 2017). , 2018, Archivos de bronconeumologia.

[32]  M. Miravitlles,et al.  Validation of clinical control in COPD as a new tool for optimizing treatment , 2018, International journal of chronic obstructive pulmonary disease.

[33]  S. Suissa,et al.  Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. , 2018, The Lancet. Respiratory medicine.

[34]  F. Venuta,et al.  Bronchoscopic treatment of emphysema: an update. , 2018, Journal of thoracic disease.

[35]  A. Morice,et al.  Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial , 2018, JAMA.

[36]  M. Humbert,et al.  Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype? , 2018, American journal of respiratory and critical care medicine.

[37]  A. Anzueto,et al.  The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD. , 2018, The American journal of medicine.

[38]  C. Montón,et al.  Clinical and Safety Outcomes of Long‐Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment , 2018, Chest.

[39]  J. Wedzicha,et al.  Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. , 2018, The Lancet. Respiratory medicine.

[40]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[41]  J. Barberà,et al.  Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. , 2018 .

[42]  M. Miravitlles,et al.  Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease. , 2017, Archivos de bronconeumologia.

[43]  J. Soriano,et al.  Asthma-COPD overlap is not a homogeneous disorder: further supporting data , 2017, Respiratory Research.

[44]  J. Soriano,et al.  Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD , 2017, European Respiratory Journal.

[45]  J. Soriano,et al.  Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease , 2017 .

[46]  M. Miravitlles,et al.  Bronchiectasis in COPD patients: more than a comorbidity? , 2017, International journal of chronic obstructive pulmonary disease.

[47]  J. Soriano,et al.  Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study , 2017, International journal of chronic obstructive pulmonary disease.

[48]  Dave Singh,et al.  Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial , 2016, The Lancet.

[49]  I. Pavord,et al.  Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. , 2016, The Lancet. Respiratory medicine.

[50]  J. Curtis,et al.  Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. , 2016, Annals of the American Thoracic Society.

[51]  R. Rodríguez-Roisín,et al.  Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. , 2016, Chest.

[52]  M. Krstic,et al.  Capsule endoscopy is useful diagnostic tool for diagnosing Meckel’s diverticulum , 2016, European journal of gastroenterology & hepatology.

[53]  J. Wedzicha,et al.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.

[54]  M. Cazzola,et al.  A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. , 2016, Chest.

[55]  I. Pavord,et al.  Treatable traits: toward precision medicine of chronic airway diseases , 2016, European Respiratory Journal.

[56]  Berend C Stoel,et al.  Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[57]  S. Johnston,et al.  Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. , 2014, The Lancet. Respiratory medicine.

[58]  Jeffrey R Stout,et al.  Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS) , 2014, Age and ageing.

[59]  Stefano Nava,et al.  Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. , 2014, The Lancet. Respiratory medicine.

[60]  L. Raiteri,et al.  Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD. , 2014, Chest.

[61]  H. Hoogsteden,et al.  Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.

[62]  L. Raiteri,et al.  Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.

[63]  V. Plaza,et al.  Calidad y fuerza: el sistema GRADE para la formulación de recomendaciones en las guías de práctica clínica , 2013 .

[64]  J. Wedzicha,et al.  Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[65]  M. Martínez-García,et al.  Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.

[66]  B. Jiang,et al.  Double-balloon enteroscopy for diagnosis of Meckel's diverticulum: comparison with operative findings and capsule endoscopy. , 2013, Surgery.

[67]  P. Coppi,et al.  Meckel’s scan in children: a review of 183 cases referred to two paediatric surgery specialist centres over 18 years , 2013, Pediatric Surgery International.

[68]  A. Morice,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011 .

[69]  W. Tom,et al.  Omphalomesenteric Duct Remnants: Umbilical versus Umbilical Cord Lesions , 2011, Pediatric dermatology.

[70]  Joan B Soriano,et al.  Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life. , 2011, Chest.

[71]  K. Rabe,et al.  Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[72]  D. D. Briggs,et al.  Evaluation of withdrawal of maintenance tiotropium in COPD. , 2009, Respiratory medicine.

[73]  Lucas M Bachmann,et al.  Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis , 2009, BMC Medicine.

[74]  N. Zhong,et al.  Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study , 2008, The Lancet.

[75]  J. E. Hansen,et al.  Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not < 70%. , 2007, Chest.

[76]  C. Snyder Current management of umbilical abnormalities and related anomalies. , 2007, Seminars in pediatric surgery.

[77]  F. Sutherland,et al.  Complications of Meckel's diverticula in adults. , 2006, Canadian journal of surgery. Journal canadien de chirurgie.

[78]  J. Sagar,et al.  Meckel's Diverticulum: a Systematic Review , 2006, Journal of the Royal Society of Medicine.

[79]  N. Zhong,et al.  Positive benefits of theophylline in a randomized, double‐blind, parallel‐group, placebo‐controlled study of low‐dose, slow‐release theophylline in the treatment of COPD for 1 year , 2006, Respirology.

[80]  A. Koch,et al.  The Significance of Meckel’s Diverticulum in Appendicitis — A Retrospective Analysis of 233 Cases , 2005, World Journal of Surgery.

[81]  John J. Park,et al.  Meckel Diverticulum: The Mayo Clinic Experience With 1476 Patients (1950–2002) , 2005, Annals of surgery.

[82]  P. Suhocki,et al.  Gastrointestinal bleeding in adult patients with Meckel's diverticulum: the role of technetium 99m pertechnetate scan. , 2002, Southern medical journal.

[83]  R. Zuwallack,et al.  Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.

[84]  Y. Maehara,et al.  Complications and diagnosis of Meckel's diverticulum in 776 patients. , 1992, American journal of surgery.

[85]  J. Escarrabill,et al.  Ventilación mecánica a domicilio , 1990 .

[86]  J. Corkery,et al.  Meckel's diverticulum: Its association with congenital malformation and the significance of atypical morphology , 1980, The British journal of surgery.

[87]  A. H. Bill,et al.  The natural history of Meckel's Diverticulum and its relation to incidental removal. A study of 202 cases of diseased Meckel's Diverticulum found in King County, Washington, over a fifteen year period. , 1976, American journal of surgery.

[88]  H. Buchsbaum Meckel's Diverticulum , 1975, Obstetrics and gynecology.

[89]  C. Olveira,et al.  Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults , 2017 .

[90]  M. Miravitlles,et al.  Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). , 2017, Archivos de bronconeumologia.

[91]  J. Soriano,et al.  Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. , 2016, Chest.

[92]  L. Puente Maestu,et al.  Continuous home oxygen therapy. , 2014, Archivos de bronconeumologia.

[93]  C. Cooper,et al.  The role of long-acting bronchodilators in the management of stable COPD. , 2004, Chest.

[94]  F. Ram,et al.  Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. , 2000, The Cochrane database of systematic reviews.